S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
SHOCKING Crypto Leak… (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The “Perfect Storm” for Gold (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden replacement revealed? (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
SHOCKING Crypto Leak… (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The “Perfect Storm” for Gold (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden replacement revealed? (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
SHOCKING Crypto Leak… (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The “Perfect Storm” for Gold (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden replacement revealed? (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
SHOCKING Crypto Leak… (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The “Perfect Storm” for Gold (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden replacement revealed? (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
TSE:IN

InMed Pharmaceuticals (IN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free IN Stock Alerts
Compare
Today's Range
N/A
50-Day Range
C$4.19
▼
C$4.19
52-Week Range
N/A
Volume
17,035 shs
Average Volume
29,552 shs
Market Capitalization
C$33.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
IN stock logo

About InMed Pharmaceuticals Stock (TSE:IN)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

IN Stock News Headlines

April 9, 2024 | americanbankingnews.com
InMed Pharmaceuticals (TSE:IN) Trading Down 1.6%
April 6, 2024 | theglobeandmail.com
InMed Pharmaceuticals (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
February 13, 2024 | finanznachrichten.de
InMed Pharmaceuticals: InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
February 13, 2024 | finance.yahoo.com
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
January 22, 2024 | theglobeandmail.com
InMed Pharmaceuticals (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat
January 16, 2024 | finance.yahoo.com
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
December 12, 2023 | finance.yahoo.com
InMed’s (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer’s with a Rare Cannabinoid Analog
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
November 30, 2023 | theglobeandmail.com
InMed Pharmaceuticals (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular Degeneration
November 29, 2023 | finance.yahoo.com
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
November 14, 2023 | msn.com
InMed Pharmaceuticals GAAP EPS of -$0.76, revenue of $901.8M
October 24, 2023 | finance.yahoo.com
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies
October 13, 2023 | benzinga.com
Cannabis Industry Report Highlights Positive Sentiment and Growth Potential at Benzinga Conference
August 11, 2023 | finanznachrichten.de
DelveInsight Business Research, LLP: Epidermolysis Bullosa Market to Surge at a CAGR of ~8% During the Study Period (2019-2032), Predicts DelveInsight
July 20, 2023 | finance.yahoo.com
InMed Provides Update on BayMedica Rare Cannabinoid Business
July 7, 2023 | msn.com
Game-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds Promise
April 25, 2023 | marketwatch.com
Biosynthesis of Cannabinoids Market Growth By 2030
April 20, 2023 | marketwatch.com
Blepharitis-Pipeline Market Description and Business Overview By 2030
March 27, 2023 | benzinga.com
InMed Pharmaceuticals: Pushing Pharma Forward With Rare Cannabinoids
March 17, 2023 | benzinga.com
Despite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023
March 13, 2023 | finance.yahoo.com
InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions
February 21, 2023 | benzinga.com
InMed Pharmaceuticals Q2 FY23 Revenue Grows 77% YoY, What About Net Loss?
February 20, 2023 | marketwatch.com
Epidermolysis Bullosa Market is Booming in Near Future 2023-2028 with Top Countries Data
February 20, 2023 | finanznachrichten.de
InMed Pharmaceuticals Inc.: InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
February 17, 2023 | yahoo.com
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
February 17, 2023 | msn.com
InMed Pharmaceuticals GAAP EPS of -$0.91, revenue of $0.47M
See More Headlines
Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
TSE:IN
CUSIP
N/A
CIK
N/A
Web
www.inmedpharma.com
Phone
604-669-7207
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
8.48
Current Ratio
2.13
Quick Ratio
1.45

Sales & Book Value

Annual Sales
C$574,677.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
10.40
Book Value
C$0.76 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
8,051,000
Free Float
N/A
Market Cap
C$33.73 million
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Eric A. Adams (Age 58)
    Pres, CEO & Director
    Comp: $488.44k
  • Ms. Alexandra Diane-Janet Mancini (Age 69)
    Sr. VP of Clinical & Regulatory Affairs
    Comp: $337.13k
  • Dr. Sazzad Hossain M.Sc. (Age 64)
    Ph.D., Co-Founder
  • Ms. Brenda Edwards C.M.A.
    CPA, Interim Chief Financial Officer
  • Mr. Michael Woudenberg P.Eng. (Age 55)
    Chief Operating Officer
  • Colin Clancy
    Sr. Director of Investor Relations
  • Mr. Jerry P. Griffin
    VP of Sales & Marketing
  • Dr. Eric Chih-Hsien Hsu (Age 52)
    Sr. VP of Preclinical R&D
  • Dr. Shane A. Johnson Ph.D.
    Sr. VP & GM of BayMedica
  • Dr. Ado Muhammad
    Sr. Consultant of Medical Affairs

Key Competitors

View All Competitors

Insiders


IN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include Organigram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU).

How do I buy shares of InMed Pharmaceuticals?

Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:IN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
How Biden has already won 2024
Porter & Company